We are live on ! Find out more
BDTX icon

Black Diamond Therapeutics
BDTX

88 hedge funds and large institutions have $717M invested in Black Diamond Therapeutics in 2020 Q3 according to their latest regulatory filings, with 19 funds opening new positions, 38 increasing their positions, 18 reducing their positions, and 11 closing their positions.

New
Increased
Maintained
Reduced
Closed

111% more repeat investments, than reductions

Existing positions increased: 38 | Existing positions reduced: 18

73% more first-time investments, than exits

New positions opened: 19 | Existing positions closed: 11

10% more funds holding

Funds holding: 80 → 88 (+8)

1.75% more ownership

Funds ownership: 64.43% → 66.17% (+1.7%)

0% more funds holding in top 10

Funds holding in top 10: 2 → 2 (0)

26% less capital invested

Capital invested by funds: $968M → $717M (-$251M)

Holders
88
Holders Change
+8
Holders Change %
+10%
% of All Funds
1.78%
Holding in Top 10
2
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.04%
New
19
Increased
38
Reduced
18
Closed
11
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Vanguard Group
Vanguard Group
Pennsylvania
+$24M
2
BlackRock
BlackRock
New York
+$10.5M
3
DM
Deerfield Management
New York
+$8.11M
4
PCM
Peregrine Capital Management
Minnesota
+$5.83M
5
IC
Ikarian Capital
Texas
+$5.52M

Top Sellers

Rank Fund Capital Flow
1
PA
Perceptive Advisors
New York
-$44M
2
BI
BVF Inc
California
-$16M
3
Wellington Management Group
Wellington Management Group
Massachusetts
-$6.53M
4
EMFAT
Emerald Mutual Fund Advisers Trust
Pennsylvania
-$4.51M
5
EA
Emerald Advisers
Pennsylvania
-$3.48M
Name Holding Trade Value Shares
Change 		Change in
Stake
NMC
1
NEA Management Company
Maryland
$104M – – –
RCM
2
RA Capital Management
Massachusetts
$78.3M – – –
BC
3
Boxer Capital
California
$60.9M – – –
Vanguard Group
4
Vanguard Group
Pennsylvania
$49.1M +$24M +788,646 +94%
AG
5
Artal Group
Luxembourg
$46M -$761K -25,000 -2%
BG
6
Bellevue Group
Switzerland
$42.4M – – –
Fidelity Investments
7
Fidelity Investments
Massachusetts
$42.3M -$830K -27,283 -2%
Wellington Management Group
8
Wellington Management Group
Massachusetts
$34.1M -$6.53M -214,505 -16%
BlackRock
9
BlackRock
New York
$33.2M +$10.5M +344,952 +46%
DM
10
Deerfield Management
New York
$24.3M +$8.11M +266,510 +50%
ACA
11
Avoro Capital Advisors
New York
$18.2M +$2.36M +77,500 +15%
DCM
12
Driehaus Capital Management
Illinois
$16.3M -$1.63M -53,448 -9%
Capital World Investors
13
Capital World Investors
California
$15.9M – – –
Federated Hermes
14
Federated Hermes
Pennsylvania
$14.4M – – –
Wells Fargo
15
Wells Fargo
California
$14M +$5.41M +177,855 +63%
Jennison Associates
16
Jennison Associates
New York
$11.1M -$1.84M -60,441 -14%
IC
17
Ikarian Capital
Texas
$10.9M +$5.52M +181,397 +102%
Franklin Resources
18
Franklin Resources
California
$9.07M +$913 +30 +0%
CC
19
Casdin Capital
New York
$8.75M – – –
State Street
20
State Street
Massachusetts
$8.43M +$1.49M +48,801 +21%
Geode Capital Management
21
Geode Capital Management
Massachusetts
$7.49M +$2.01M +65,962 +36%
Northern Trust
22
Northern Trust
Illinois
$6.22M +$2.26M +74,398 +57%
JP Morgan Chase
23
JP Morgan Chase
New York
$6.2M +$3.96M +130,245 +177%
PCM
24
Peregrine Capital Management
Minnesota
$5.79M +$5.83M +191,500 New
Lord, Abbett & Co
25
Lord, Abbett & Co
New Jersey
$4.65M -$302K -9,933 -6%
1
2 3 4

BDTX Hedge Fund Activity: Q3 2020 in Review

88 of the 4,957 institutional investors tracked by Wall St. Rank reported a position in Black Diamond Therapeutics (BDTX) for Q3 2020, worth a combined $717M — down 26% from $968M a quarter earlier.

Buyers outnumbered sellers: 19 funds opened new BDTX positions and 11 closed out — a net gain of 8 holders — while 38 added to existing stakes and 18 trimmed.

The largest buyer was Vanguard Group, adding an estimated $24M. The largest seller was Perceptive Advisors, exiting entirely with an estimated $44M sold.

  • 88 institutional investors held Black Diamond Therapeutics (BDTX) as of Q3 2020, up from 80 in Q2 2020.
  • Funds reported $717M of Black Diamond Therapeutics stock for Q3 2020, down 26% quarter-over-quarter.
  • 19 funds opened new Black Diamond Therapeutics positions in Q3 2020 and 11 closed out, a net change of +8 holders.
  • The largest Black Diamond Therapeutics buyer in Q3 2020 was Vanguard Group, an estimated $24M added.
  • The largest Black Diamond Therapeutics seller in Q3 2020 was Perceptive Advisors, an estimated $44M sold.

Based on aggregated 13F filings for Q3 2020.